奥氮平与其他第二代抗精神病药物在改善精神分裂症患者洞察力和停药率方面的比较。

Hongbo He, Yanling Zhou, Mingzhe Yang, Xiongxiong Li, Yu-Tao Xiang, Jiandong Luo
{"title":"奥氮平与其他第二代抗精神病药物在改善精神分裂症患者洞察力和停药率方面的比较。","authors":"Hongbo He,&nbsp;Yanling Zhou,&nbsp;Mingzhe Yang,&nbsp;Xiongxiong Li,&nbsp;Yu-Tao Xiang,&nbsp;Jiandong Luo","doi":"10.11919/j.issn.1002-0829.217087","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In the last decade, olanzapine became widely used in mental health service worldwide even after being criticized for its metabolic side effects. Patients with schizophrenia on olanzapine were usually found to stay on their medications longer than the other second-generation antipsychotics (SGAs) except clozapine. The reason for this is unknown.</p><p><strong>Objective: </strong>This prospective study compared the influences of olanzapine and other SGAs except clozapine on improving insight and medication discontinuation rate in schizophrenia.</p><p><strong>Methods: </strong>A total of 148 patients with schizophrenia medically indicated for initiation of treatment with olanzapine or other SGAs were evaluated for symptoms, insight, attitudes toward medication, side effects, body weight and fasting lipid and glucose parameters at admission and before discharge, and follow-up calls one-year after discharge documented whether they were regularly taking prescribed psychotropic medication or not.</p><p><strong>Results: </strong>After an average of 72.8 days of inpatient treatment, the olanzapine and other SGAs group exhibited similar levels of symptom improvement with an average reduction of 28.7 in the Positive and Negative Syndrome Scale (PANSS) total score. The Olanzapine group exhibited better improvement in insight assessed using the G12 item of PANSS and Insight and Treatment Attitudes Questionnaire (ITAQ), more metabolic side effects indexed with total cholesterol, triglycerides levels and weight gain, and a lower medication discontinuation rate than the other SGAs group.</p><p><strong>Conclusion: </strong>Although general symptom improvement was similar, olanzapine significantly improved insight and presented less medication discontinuation compared to other SGAs, which might partially explain why patients on olanzapine stayed longer on their medications.</p>","PeriodicalId":21886,"journal":{"name":"上海精神医学","volume":"30 3","pages":"178-187"},"PeriodicalIF":0.0000,"publicationDate":"2018-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.11919/j.issn.1002-0829.217087","citationCount":"9","resultStr":"{\"title\":\"Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia.\",\"authors\":\"Hongbo He,&nbsp;Yanling Zhou,&nbsp;Mingzhe Yang,&nbsp;Xiongxiong Li,&nbsp;Yu-Tao Xiang,&nbsp;Jiandong Luo\",\"doi\":\"10.11919/j.issn.1002-0829.217087\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In the last decade, olanzapine became widely used in mental health service worldwide even after being criticized for its metabolic side effects. Patients with schizophrenia on olanzapine were usually found to stay on their medications longer than the other second-generation antipsychotics (SGAs) except clozapine. The reason for this is unknown.</p><p><strong>Objective: </strong>This prospective study compared the influences of olanzapine and other SGAs except clozapine on improving insight and medication discontinuation rate in schizophrenia.</p><p><strong>Methods: </strong>A total of 148 patients with schizophrenia medically indicated for initiation of treatment with olanzapine or other SGAs were evaluated for symptoms, insight, attitudes toward medication, side effects, body weight and fasting lipid and glucose parameters at admission and before discharge, and follow-up calls one-year after discharge documented whether they were regularly taking prescribed psychotropic medication or not.</p><p><strong>Results: </strong>After an average of 72.8 days of inpatient treatment, the olanzapine and other SGAs group exhibited similar levels of symptom improvement with an average reduction of 28.7 in the Positive and Negative Syndrome Scale (PANSS) total score. The Olanzapine group exhibited better improvement in insight assessed using the G12 item of PANSS and Insight and Treatment Attitudes Questionnaire (ITAQ), more metabolic side effects indexed with total cholesterol, triglycerides levels and weight gain, and a lower medication discontinuation rate than the other SGAs group.</p><p><strong>Conclusion: </strong>Although general symptom improvement was similar, olanzapine significantly improved insight and presented less medication discontinuation compared to other SGAs, which might partially explain why patients on olanzapine stayed longer on their medications.</p>\",\"PeriodicalId\":21886,\"journal\":{\"name\":\"上海精神医学\",\"volume\":\"30 3\",\"pages\":\"178-187\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.11919/j.issn.1002-0829.217087\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"上海精神医学\",\"FirstCategoryId\":\"95\",\"ListUrlMain\":\"https://doi.org/10.11919/j.issn.1002-0829.217087\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"上海精神医学","FirstCategoryId":"95","ListUrlMain":"https://doi.org/10.11919/j.issn.1002-0829.217087","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 9

摘要

背景:近十年来,奥氮平在受到代谢副作用的批评后,在世界范围内被广泛应用于精神卫生服务。服用奥氮平的精神分裂症患者通常比除氯氮平外的其他第二代抗精神病药物(SGAs)服药时间更长。其原因尚不清楚。目的:本前瞻性研究比较奥氮平与除氯氮平外的其他SGAs对精神分裂症患者改善洞察力和停药率的影响。方法:对148例精神分裂症患者在入院和出院时的症状、见解、用药态度、副作用、体重、空腹血脂和血糖指标进行评估,并在出院后1年进行随访,记录患者是否定期服用处方精神药物。结果:在平均72.8天的住院治疗后,奥氮平组和其他SGAs组的症状改善水平相似,阳性和阴性综合征量表(PANSS)总分平均下降28.7分。使用PANSS的G12项目和洞察力和治疗态度问卷(ITAQ)评估,奥氮平组在洞察力方面表现出更好的改善,以总胆固醇,甘油三酯水平和体重增加为指标的代谢副作用更多,停药率低于其他SGAs组。结论:虽然总体症状改善相似,但与其他SGAs相比,奥氮平显著改善了洞察力,停药的情况更少,这可能部分解释了为什么服用奥氮平的患者服药时间更长。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia.

Background: In the last decade, olanzapine became widely used in mental health service worldwide even after being criticized for its metabolic side effects. Patients with schizophrenia on olanzapine were usually found to stay on their medications longer than the other second-generation antipsychotics (SGAs) except clozapine. The reason for this is unknown.

Objective: This prospective study compared the influences of olanzapine and other SGAs except clozapine on improving insight and medication discontinuation rate in schizophrenia.

Methods: A total of 148 patients with schizophrenia medically indicated for initiation of treatment with olanzapine or other SGAs were evaluated for symptoms, insight, attitudes toward medication, side effects, body weight and fasting lipid and glucose parameters at admission and before discharge, and follow-up calls one-year after discharge documented whether they were regularly taking prescribed psychotropic medication or not.

Results: After an average of 72.8 days of inpatient treatment, the olanzapine and other SGAs group exhibited similar levels of symptom improvement with an average reduction of 28.7 in the Positive and Negative Syndrome Scale (PANSS) total score. The Olanzapine group exhibited better improvement in insight assessed using the G12 item of PANSS and Insight and Treatment Attitudes Questionnaire (ITAQ), more metabolic side effects indexed with total cholesterol, triglycerides levels and weight gain, and a lower medication discontinuation rate than the other SGAs group.

Conclusion: Although general symptom improvement was similar, olanzapine significantly improved insight and presented less medication discontinuation compared to other SGAs, which might partially explain why patients on olanzapine stayed longer on their medications.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
2341
期刊介绍:
期刊最新文献
Research Progress in Biological Studies of Schizophrenia in China in 2017. An Association Study on the Cognitive Function and the Cerebral Grey Matter Volume of Patients with First-Episode Schizophrenia. A Comparison Study of Working Memory Deficits between Patients with Methamphetamine-Associated Psychosis and Patients with Schizophrenia. Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia. The Effect of Repetitive Transcranial Magnetic Stimulation on the Reinstatement of Methamphetamine-Induced Conditioned Place Preference in Rats.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1